What question did this study set out to answer?

To establish evidence-based guidelines for acute and prophylactic bleeding management using desmopressin and VWF/FVIII concentrates in surgical patients with type 1, 2, and 3 von Willebrand disease.

January 1, 2009Acta Haematologica

Managing Patients with von Willebrand Disease Type 1, 2 and 3 with Desmopressin and von Willebrand Factor-Factor VIII Concentrate in Surgical Settings

View Full Paper

Ask AI

Bookmark

Population

Patients with von Willebrand disease (VWD) type 1, 2, and 3 in surgical settings

Design

Guideline

Authors

JMJan MichielsVlaams Instituut voor Biotechnologie HVHuub H.D.M. van VlietLeiden University ZBZwi BernemanUniversity of Antwerp

Discussion

Member takes

Implication

VWF:RCo-based dosing should now guide VWD bleeding and surgical management; extends prior guidelines with severity-stratified protocols.

Key Points

To establish evidence-based guidelines for acute and prophylactic bleeding management using desmopressin and VWF/FVIII concentrates in surgical patients with type 1, 2, and 3 von Willebrand disease.
Assessed VWF/FVIII concentrate composition and efficacy using FVIII coagulant activity (FVIII:C), ristocetin cofactor activity (VWF:RCo), collagen binding, and multimeric structure profiling.
Formulated dosing protocols stratified by disease subtype (types 1, 2, and 3), surgical invasiveness (minor vs. major), and patient bleeding scores.
Identified distinct pharmacokinetic profiles and coagulant requirements across subtypes, noting subnormal FVIII:C levels in moderate type 2 disease compared with severely deficient levels in type 3 disease.
Established a VWF:RCo unit-based dosing framework to standardize acute and prophylactic hemostatic management during surgical interventions.

Structured PICO

Population

Patients with von Willebrand disease (VWD) type 1, 2, and 3 in surgical settings

Intervention

Desmopressin and von Willebrand factor (VWF)/factor VIII (FVIII) concentrate

Outcome

Acute and prophylactic treatment of bleeding

Proposes new guidelines for dosing VWF/FVIII concentrates based on VWF:RCo units for managing bleeding in VWD patients undergoing surgery.

Cite This Study

Michiels et al. (2009) studied this question.

synapsesocial.com/papers/6a7105ebabc331a85807a2ee https://doi.org/10.1159/000214857

View Full Paper

Ask AI

Bookmark

Managing Patients with von Willebrand Disease Type 1, 2 and 3 with Desmopressin and von Willebrand Factor-Factor VIII Concentrate in Surgical Settings

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Managing Patients with von Willebrand Disease Type 1, 2 and 3 with Desmopressin and von Willebrand Factor-Factor VIII Concentrate in Surgical Settings

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider